Three of the four RCTs were pooled to assess the risk of AKI, and the results demonstrated that SGLT2 inhibitors significantly reduced the risk of AKI by 19% compared to the placebo (RR = 0.81, 95% CI: 0.69–0.97, I2 = 0%, Figure 7d). Here, SLC5A2 is linked to acute kidney injury.